- Home
- ABL vs ORKA Comparison
ABL vs ORKA Comparison
Compare ABL & ORKA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ABL
- ORKA
- Stock Information
- Founded
- ABL 2004
- ORKA 2004
- Country
- ABL United States
- ORKA United States
- Employees
- ABL N/A
- ORKA N/A
- Industry
- ABL Investment Managers
- ORKA Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- ABL Finance
- ORKA Health Care
- Exchange
- ABL Nasdaq
- ORKA Nasdaq
- Market Cap
- ABL 661.9M
- ORKA 580.3M
- IPO Year
- ABL N/A
- ORKA N/A
- Fundamental
- Price
- ABL $6.67
- ORKA $14.90
- Analyst Decision
- ABL Strong Buy
- ORKA Strong Buy
- Analyst Count
- ABL 3
- ORKA 8
- Target Price
- ABL $12.83
- ORKA $40.43
- AVG Volume (30 Days)
- ABL 516.1K
- ORKA 135.1K
- Earning Date
- ABL 11-06-2025
- ORKA 11-12-2025
- Dividend Yield
- ABL N/A
- ORKA N/A
- EPS Growth
- ABL N/A
- ORKA N/A
- EPS
- ABL N/A
- ORKA N/A
- Revenue
- ABL $161,724,466.00
- ORKA N/A
- Revenue This Year
- ABL $77.22
- ORKA N/A
- Revenue Next Year
- ABL $29.93
- ORKA N/A
- P/E Ratio
- ABL N/A
- ORKA N/A
- Revenue Growth
- ABL 69.56
- ORKA N/A
- 52 Week Low
- ABL $4.60
- ORKA $5.49
- 52 Week High
- ABL $10.95
- ORKA $31.13
- Technical
- Relative Strength Index (RSI)
- ABL 52.49
- ORKA 48.46
- Support Level
- ABL N/A
- ORKA $15.23
- Resistance Level
- ABL $6.63
- ORKA $16.21
- Average True Range (ATR)
- ABL 0.27
- ORKA 0.96
- MACD
- ABL -0.30
- ORKA -0.09
- Stochastic Oscillator
- ABL 92.90
- ORKA 12.78
About ABL Abacus Life Inc.
Abacus Global Management Inc is a financial services company specializing in alternative asset management, data-driven wealth solutions, technology innovations, and institutional services. The Company organizes its business into five reportable segments Active Management, Originations, Asset Management, Portfolio Servicing, and Technology Services. Its operations are confined to the United States.
About ORKA Oruka Therapeutics Inc. Common Stock
Oruka Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its lead program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. The company's co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, psoriatic arthritis (PsA), and other conditions. These programs each bind their respective targets at high affinity and incorporate half-life extension technology to increase exposure and decreasing dosing frequency.